Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
Recruiting
Phase 1
Phase 2
Interventional Study
HER2-Positive Solid Tumor
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 147 (estimated)
- Sponsor
- Yuhan Corporation · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This first-in-human study will be counducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive Locally Advanced or Metastatic Solid Tumors.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
\[Dose Escalation Part\]
* Pathologically confirmed HER2-positive
* Mandatory provision of tumor tissue sample
\[Dose Expansion Part\]
* Patients who have at least one measurable lesion
* Mandatory provision of tumor tissue sample
1. Cohort 1: Pathologically confirmed HER2…
Contacts